Purpose: To investigate the interactions occurring at the interface between some currently used vitreous tamponading substances and the ocular tissues, in an early follow-up after surgery. Methods: Adult albino rabbit eyes underwent vitrectomy and were injected intravitreally with silicone oils at 1,000 or 3,000 cSt, fluorosilicone oil and perfluorodecalin. Different morphological techniques (light microscopy, scanning and electron microscopy, immunohistochemistry) were applied. Results: All the tested materials, although non-toxic, penetrate the ocular tissues also at the anterior segment level, and in the long-term follow-up this can yield functional impairment. No massive inflammation has been detected in the zones in contact with the materials, but immunoglobulins and complement fractions are anyway present in the stroma of various tissues and around the droplets of emulsified materials, suggesting a local immune reaction. Conclusions: Data from this study confirmed that a permanent vitreous substitute, showing a perfect biocompatibility, still does not exist. The indication to remove the tamponading substance within 2 months after the surgery emerges from this investigation, confirming previous studies. Despite some negative features, silicone oil still appears the most biocompatible material for vitreous replacement.

1.
Gabel VP, Kampik A, Gabel CH, Spiegel D: Silicone oil with high specific gravity for intraocular use. Br J Ophthalmol 1987;71:262–267.
2.
Gabel VP, Kampik A, Burkhardt J: Analysis of intraocularly applied silicone oils of various origins. Graefe’s Arch Clin Exp Ophthalmol 1987;225:160–162.
3.
Haut J, Larricart JP, Van Effenterre G, Pinon-Pignero FI: Some of the most important properties of silicone oil to explain its action. Ophthalmologica 1985;191:150–153.
4.
Parel JM: Silicone oils: Physicochemical properties; in Glaser GM, Michels RG (eds): Retina. St Louis, Mosby, 1989, vol 3, pp 261–277.
5.
Gremillion CM Jr, Peyman GA, Liu KR, Naguib KS: Fluorosilicone oil in the treatment of retinal detachment. Br J Ophthalmol 1990;74:643–646.
6.
Miyamoto L, Refojo MF, Tolentino FI, Fournier SA: Fluorinated oils as experimental vitreous substitutes. Arch Ophthalmol 1986;104:1053–1056.
7.
Chang S, Zimmermann NJ, Iwamoto T, Ortiz R: Experimental vitreous replacement with perfluorotributylamine. Am J Ophthalmol 1987;103:29–37.
8.
Chang S, Reppucci V, Zimmermann NJ, Heinemann MH: Perfluorocarbon liquids in the management of traumatic retinal detachments. Ophthalmology 1989;96:785–792.
9.
Mathis A: Experimental tolerance of perfluorodecalin. J Vitreoretina 1992;1:26–27.
10.
Meinert H: Requirements of perfluorocarbons for use in ophthalmology. J Vitreoretina 1992;1:5–16.
11.
Chan C, Okun E: The question of ocular tolerance to intravitreal liquid silicone: A long-term analysis. Ophthalmology 1986;93:651–660.
12.
Mukai N, Lee PF, Oguri M, Schepens CL: A long-term evaluation of silicone retinopathy in monkeys. Can J Ophthalmol 1975;10:391–402.
13.
Cellini M, Versura P, Maltarello MC, Profazio V, Baldi A, Zucchini PG, Caramazza R: Comparison between silicon and vitamin E oils as inner tamponade materials: An experimental study; in Caramazza R, Versura P (eds): Biomaterials in Ophthalmology: An Interdisciplinary Approach. Bologna, ER Congressi Publisher, 1990, pp 359–364.
14.
Bottoni F, Sborgia M, Arpa P, De Casa N, Bertazzi E, Monticelli M, De Molfetta V: Perfluorocarbon liquids as postoperative short-term vitreous substitutes in complicated retinal detachment. Graefe’s Arch Clin Exp Ophthalmol 1993;231:619–628.
15.
Eckardt C, Schmidt D, Czank M: Intraocular tolerance to silicone oils of different specific gravities: An experimental study. Ophthalmologica 1990;201:133–139.
16.
Gonvers M, Hornung JP, de Courten C: The effect of liquid silicone on the rabbit retina: Histologic and ultrastructural study. Arch Ophthalmol 1986;104:1057–1062.
17.
Labelle P, Okun E: Ocular tolerance to liquid silicone: An experimental study. Can J Ophthalmol 1972;7:199–204.
18.
Ohira A, Wilson CA, de Juan E, Murata Y: Experimental retinal tolerance to emulsified silicone oil. Retina 1991;11:259–265.
19.
Refojo MF, Roldan M, Leong FL, Henriquez AS: Effect of silicone oil on the cornea. J Biomed Materials Res 1985;19:643–652.
20.
Versura P, Maltarello MC, Cellini M, Caramazza R, Laschi R: Correlative study of 1,000 and 3,000 cts silicone oils injected in rabbit vitreous chamber: Morphological and immunohistochemical aspects; in Pizzoferrato A, Marchetti PG, Lee J (eds): Biomaterials and Clinical Applications. Amsterdam, Elsevier Science Publisher, 1987, pp 349–432.
21.
Chuo N, Wang WJ, Albert DM, Schepens CL: Intravitreous silicone injection: Histopathologic findings in a human eye after 12 years. Arch Ophthalmol 1983;101:1399–1401.
22.
Laroche L, Pavlakis C, Saraux H, Orcel L: Ocular findings following intravitreal silicone injection. Arch Ophthalmol 1983;101:1422–1425.
23.
Parmley VC, Barishak YR, Howes EL, Crawford JB: Foreign-body giant cell reaction to liquid silicone. Am J Ophthalmol 1986;101:680–683.
24.
Pham Huy C, Larricart P, Warnet JM, Haut J: In vitro laser decomposition of silicone fluid used in detachment of the retina. Ophthalmologica 1992;204:23–26.
25.
Sugar HS, Okamura ID: Ocular findings six years after intravitreal silicone injection. Arch Ophthalmol 1976;94:612–615.
26.
Riess JG: Fluorocarbon-based oxygen carriers: New orientations. Artif Organs 1991;15:408–413.
27.
Wilson CA, Berkowitz BA, Srebro R: Perfluorinated organic liquid as an intraocular oxygen reservoir for the ischemic retina. Invest Ophthalmol Vis Sci 1995;36:131–141.
28.
Moreira H, de Queiroz JM Jr, Ligget PE, McDonnell PJ: Corneal toxicity study of two perfluorocarbon liquids in rabbit eyes. Cornea 1992;11:376–379.
29.
Refojo MF, Leong FL, Chung H, Hueno N: Extraction of retinol and cholesterol by intraocular silicone oils. Ophthalmology 1988;95:614–618.
30.
Bornfeld N, El-Hifnawi ES, Laqua H: Ultrastructural characteristics of preretinal membranes from human eyes filled with silicone oil. Am J Ophthalmol 1987;103:770–775.
31.
Jerdan JA, Pepose JS, Michels RG, Hayashi H: Proliferative vitreoretinopathy membranes: An immunohistochemical study. Ophthalmology 1989;96:801–810.
32.
Lewis H, Burke JM, Abrams GW, Aaberg TM: Perisilicone proliferation after vitrectomy for proliferative vitreoretinopathy. Ophthalmology 1988;95:583–591.
33.
Sato M, Sato Y, Shimada H, Aso S: Epiretinal membrane formation after silicone oil tamponade in vitrectomized monkey eye. Chibret Int I J Ophthalmol 1991;8:40–48.
34.
Sparrow JR, Ortiz R, MacLeish PR, Chang S: Fibroblast behaviour at aqueous interfaces with perfluorocarbon, silicone and fluorosilicone liquids. Invest Ophthalmol Vis Sci 1990;31:638–646.
35.
Friberg TR, Verstreaten TC, Wilcox DK: Effects of emulsification, purity and fluorination of silicone oil on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1991;32:2030–2034.
36.
Verstraeten TC, Wilcox DK, Friberg TR, Reel C: Effects of silicone oil and hyaluronic acid on cultured human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1990;31:1761–1766.
37.
Nakamura K, Refojo MF, Crabtree DV, Leong FL: Analysis and fractionation of silicone and fluorosilicone oils for intraocular use. Invest Ophthalmol Vis Sci 1990;31:2059–2069.
38.
Nakamura K, Refojo MF, Crabtree DV, Pastor J: Ocular toxicity of low-molecular-weight components of silicone and fluorosilicone oils. Invest Ophthalmol Vis Sci 1991;32:3007–3020.
39.
Nakamura K, Refojo MF, Crabtree DV: Factors contributing to the emulsification of intraocular silicone and fluorosilicone oils. Invest Ophthalmol Vis Sci, 1990;31:647–656.
40.
Chirila TV, Tahija S, Hong Y, Vijayasekaran S, Constable IJ: Synthetic polymers as materials for artificial vitreous body: Review and recent advances. J Biomater Appl 1994;9:121–137.
41.
Hegazy HM, Peyman GA, Liang C, Unal MH, Molinari LC, Kazi AA: Use of perfluorocarbon liquids, silicone oil, and 5-fluorouracil in the management of experimental PVR. Int Ophthalmol 1998–99;22:239–246.
42.
Nakagawa M, Tanaka M, Miyata T: Evaluation of collagen gel and hyaluronic acid as vitreous substitutes. Ophthalmic Res 1997;29:409–420.
43.
Hong Y, Chirila TV, Vijayasekaran S, Dalton PD, Tahija SG, Cuypers MJ, Constable IJ: Crosslinked poly(1-vinyl-2-pyrrolidinone) as vitreous substitute. J Biomed Mater Res 1996;30:441–448.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.